Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections.

Vincent Trebosc, Christian Kemmer, Sergio Lociuro, Marc Gitzinger, Glenn E Dale

Drug discovery today 2021 Sep

filter terms:

Rifamycin antibiotics were discovered during the 1950s, and their main representative, rifampicin, remains a cornerstone treatment for TB. The clinical use of rifamycin is restricted to mycobacteria and Gram-positive infections because of its poor ability to penetrate the Gram-negative outer membrane. Rifabutin, a rifamycin antibiotic approved for the prevention of Mycobacterium avium complex disease, makes an exception to this rule by hijacking the iron uptake system of Acinetobacter baumannii, resulting in potent activity against this important Gram-negative pathogen. Here, we describe recent findings on the specific activity of rifabutin and provide evidence of the need for the development of an intravenous formulation of rifabutin (BV100) for the treatment of difficult-to-treat carbapenem-resistant A.baumannii infections. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Vincent Trebosc, Christian Kemmer, Sergio Lociuro, Marc Gitzinger, Glenn E Dale. Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections. Drug discovery today. 2021 Sep;26(9):2099-2104